{"id":52309,"date":"2022-12-22T21:02:11","date_gmt":"2022-12-22T20:02:11","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/the-worldwide-microbiome-therapeutics-industry-is-projected-to-reach-4-7-billion-by-2027-researchandmarkets-com\/"},"modified":"2022-12-22T21:02:11","modified_gmt":"2022-12-22T20:02:11","slug":"the-worldwide-microbiome-therapeutics-industry-is-projected-to-reach-4-7-billion-by-2027-researchandmarkets-com","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/the-worldwide-microbiome-therapeutics-industry-is-projected-to-reach-4-7-billion-by-2027-researchandmarkets-com\/","title":{"rendered":"The Worldwide Microbiome Therapeutics Industry is Projected to Reach $4.7 Billion by 2027 – ResearchAndMarkets.com"},"content":{"rendered":"
\n

DUBLIN–(BUSINESS WIRE)–The “Microbiome Therapeutics: Global Strategic Business Report”<\/a> has been added to ResearchAndMarkets.com’s<\/strong> offering.\n<\/p>\n

<\/a><\/p>\n

\nThe global market for Microbiome Therapeutics estimated at US$199.1 Million in the year 2020, is projected to reach a revised size of US$4.7 Billion by 2027, growing at a CAGR of 57.2% over the analysis period 2020-2027.\n<\/p>\n

\nC. Difficile Infection, one of the segments analyzed in the report, is projected to record a 53.9% CAGR and reach US$1.8 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Obesity segment is readjusted to a revised 57.2% CAGR for the next 7-year period.\n<\/p>\n

\nThe U.S. Market is Estimated at $60.7 Million, While China is Forecast to Grow at 54.6% CAGR<\/strong>\n<\/p>\n

\nThe Microbiome Therapeutics market in the U.S. is estimated at US$60.7 Million in the year 2020. China, the world’s second largest economy, is forecast to reach a projected market size of US$749.9 Million by the year 2027 trailing a CAGR of 54.6% over the analysis period 2020 to 2027.\n<\/p>\n

\nAmong the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 50.7% and 48.8% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 38.6% CAGR.\n<\/p>\n

\nPrimary Hyperoxyurea Segment to Record 60.2% CAGR<\/strong>\n<\/p>\n

\nIn the global Primary Hyperoxyurea segment, USA, Canada, Japan, China and Europe will drive the 60.2% CAGR estimated for this segment.\n<\/p>\n

\nThese regional markets accounting for a combined market size of US$32.5 Million in the year 2020 will reach a projected size of US$879.9 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets.\n<\/p>\n

\nSelect Competitors (Total 46 Featured) –<\/strong>\n<\/p>\n